M&A Deal Summary

Abbott Laboratories Acquires Bigfoot Biomedical

On September 5, 2023, Abbott Laboratories acquired medical products company Bigfoot Biomedical

Acquisition Highlights
  • This is Abbott Laboratories’ 20th transaction in the Medical Products sector.
  • This is Abbott Laboratories’ 27th transaction in the United States.
  • This is Abbott Laboratories’ 14th transaction in California.

M&A Deal Summary
Date 2023-09-05
Target Bigfoot Biomedical
Sector Medical Products
Buyer(s) Abbott Laboratories
Deal Type Add-on Acquisition

Target

Bigfoot Biomedical

Milpitas, California, United States
Bigfoot Biomedical is a health solution company focused on optimizing the care of people with T1D by leveraging data, smart devices and people to deliver improved outcomes valued by patients, providers and payers. Bigfoot Biomedical was founded in 2014 and is based in Milpitas, California.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Abbott Laboratories

North Chicago, Illinois, United States
Category Company
Founded 1888
Sector Medical Products
Employees114,000
Revenue 40.1B USD (2023)
DESCRIPTION
Entrance to Abbott's corporate campus in Abbott Park, Illinois.
Entrance to Abbott's corporate campus in Abbott Park, Illinois.

Abbott Laboratories is a diversified, global provider of diagnostics, medical devices, nutrition and pharmaceuticals. Abbott Laboratories was incorporated in 1888 and is headquartered in North Chicago, Illinois.

DEAL STATS #
Overall 35 of 35
Sector (Medical Products) 20 of 20
Type (Add-on Acquisition) 35 of 35
State (California) 14 of 14
Country (United States) 27 of 27
Year (2023) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-02-08 CSI

St. Paul, Minnesota, United States

CSI is a medical device company focused on developing and commercializing minimally invasive treatment solutions for vascular disease. Its primary products include catheter-based platforms, such as the Stealth 360° peripheral artery disease (PAD) System, Diamondback 360° PAD System, and Diamondback Predator 360° PAD System that are used for the treatment of a range of plaque types in leg arteries above and below the knee. CSI was founded in 1989 and is based in St. Paul, Minnesota.

Buy $890M
Mergr

Product

Company

Legal